4.6 Article

Effects of the TP53 p.R249S mutant on proliferation and clonogenic properties in human hepatocellular carcinoma cell lines: interaction with hepatitis B virus X protein

Journal

CARCINOGENESIS
Volume 31, Issue 8, Pages 1475-1482

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/carcin/bgq118

Keywords

-

Categories

Funding

  1. Ligue Nationale Contre le Cancer (France)
  2. Association pour la Recherche sur le Cancer (France) [3117, 5044]

Ask authors/readers for more resources

Aflatoxin B(1) (AFB(1)) is a risk factor for hepatocellular carcinoma (HCC) in many low-resource countries. Although its metabolites bind at several positions in TP53, a mutation at codon 249 (AGG to AGT, arginine to serine, p.R249S) accounts for 90% of TP53 mutations in AFB(1)-related HCC. This specificity suggests that p.R249S confers a selective advantage during hepatocarcinogenesis. Using HCC cell lines, we show that p.R249S has lost the capacity to bind to p53 response elements and to transactivate p53 target genes. In p53-null Hep3B cells, stable transfection of p.R249S or of another mutant, p.R248Q, did not induce significant changes in cell proliferation and survival after cytotoxic stress. In contrast, in a cell line that constitutively expresses both p.R249S and the hepatitis B virus antigen HBx (PLC/PRF/5), silencing of either p.R249S or HBx by RNA interference slowed down proliferation, with no additive effects when both factors were silenced. Furthermore, the two proteins appear to form a complex. In human HCC samples, mutation at codon 249 did not correlate with p.R249S protein accumulation or HBx truncation status. We suggest that p.R249S may contribute to hepatocarcinogenesis through interaction with HBx, conferring a subtle growth advantage at early steps of the transformation process, but that this interaction is not required for progression to advanced HCC.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Pathology

Percentage grade 4 tumour predicts outcome for prostate adenocarcinoma in needle biopsies from patients with advanced disease: 10-year data from the TROG 03.04 RADAR trial

B. Delahunt, A. Steigler, C. Atkinson, D. Christie, G. Duchesne, L. Egevad, D. Joseph, D. N. Kenwright, J. Matthews, J. D. Murray, C. Oldmeadow, H. Samaratunga, N. A. Spry, M. C. Thunders, H. Hondermarck, J. W. Denham

Summary: Previous reports have shown that quantifying high tumour grade in prostate cancer patients is of prognostic significance. This study found that the length, percentage, and absolute values of Gleason pattern 4 (GP4) were significantly associated with distant progression of tumour, all-cause mortality, and cancer-specific mortality over a 10-year follow-up period. In addition, these parameters outperformed the division of cases according to Gleason score in terms of prognostic significance.

PATHOLOGY (2022)

Article Endocrinology & Metabolism

Ductal and acinar components of mixed prostatic adenocarcinoma frequently have a common clonal origin

Claes Lindh, Hemamali Samaratunga, Brett Delahunt, Rebecka Bergstrom, Venkatesh Chellappa, John Yaxley, Johan Lindberg, Lars Egevad

Summary: Most ductal and acinar prostate adenocarcinoma components of mixed tumors share the same clonal origin. Ductal adenocarcinoma components often exhibit genome doubling events leading to aneuploidy, consistent with the aggressive nature of high grade prostate cancer.

PROSTATE (2022)

Article Radiology, Nuclear Medicine & Medical Imaging

Primary tumour PSMA intensity is an independent prognostic biomarker for biochemical recurrence-free survival following radical prostatectomy

Matthew J. Roberts, Andrew Morton, Nathan Papa, Anthony Franklin, Sheliyan Raveenthiran, William J. Yaxley, Geoffrey Coughlin, Troy Gianduzzo, Boon Kua, Louise McEwan, David Wong, Brett Delahunt, Lars Egevad, Hemamali Samaratunga, Nicholas Brown, Robert Parkinson, Louise Emmett, John W. Yaxley

Summary: PSMA intensity on PSMA PET/CT is a clinically significant biomarker for predicting oncological outcomes and biochemical recurrence-free survival in patients undergoing radical prostatectomy.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2022)

Editorial Material Microbiology

Special Issue: Updates on HBV Infection

Isabelle Chemin, Flor Helene Pujol

MICROORGANISMS (2022)

Letter Pathology

Late recurrence of renal solitary fibrous tumour in the contralateral kidney

Hemamal Samaratunga, Tony Gianduzzo, Joanna Perry-Keene, Lars Egevad, Brett Delahunt

PATHOLOGY (2023)

Article Cell Biology

Interobserver reproducibility of cribriform cancer in prostate needle biopsies and validation of International Society of Urological Pathology criteria

Lars Egevad, Brett Delahunt, Kenneth A. Iczkowski, Theo van der Kwast, Geert J. L. H. van Leenders, Katia R. M. Leite, Chin-Chen Pan, Hemamali Samaratunga, Toyonori Tsuzuki, Nita Mulliqi, Xiaoyi Ji, Henrik Olsson, Masi Valkonen, Pekka Ruusuvuori, Martin Eklund, Kimmo Kartasalo

Summary: There is evidence that cribriform morphology is associated with a worse prognosis for prostatic adenocarcinoma. This study aimed to investigate the reproducibility of cribriform cancer diagnosis in prostate needle biopsies. A panel of nine prostate pathology experts independently reviewed 304 digitised biopsies and achieved a 2/3 consensus diagnosis of cribriform and noncribriform cancer in 90% of the cases. Strict diagnostic criteria were used to identify cribriform patterns and generate a set of consensus cases for standardization.

HISTOPATHOLOGY (2023)

Article Medicine, General & Internal

Computational pathology in 2030: a Delphi study forecasting the role of AI in pathology within the next decade

M. Alvaro Berbis, David S. McClintock, Andrey Bychkov, Jeroen Van der Laak, Liron Pantanowitz, Jochen K. Lennerz, Jerome Y. Cheng, Brett Delahunt, Lars Egevad, Catarina Eloy, Alton B. Farris III, Filippo Fraggetta, Raimundo Garcia del Moral, Douglas J. Hartman, Markus D. Herrmann, Eva Hollemans, Kenneth A. Iczkowski, Aly Karsan, Mark Kriegsmann, Mohamed E. Salama, John H. Sinard, J. Mark Tuthill, Bethany Williams, Cesar Casado-Sanchez, Victor Sanchez-Turrion, Antonio Luna, Jose Aneiros-Fernandez, Jeanne Shen

Summary: AI is expected to be routinely and impactfully used in pathology practice by 2030, according to experts in the field. This consensus study highlights the anticipated short-to-mid-term impact of AI and raises important practical, ethical, and legal challenges that need to be addressed prior to its clinical implementation.

EBIOMEDICINE (2023)

Article Oncology

Application of Genomic Sequencing to Refine Patient Stratification for Adjuvant Therapy in Renal Cell Carcinoma

Naveen S. Vasudev, Ghislaine Scelo, Kate I. Glennon, Michelle Wilson, Louis Letourneau, Robert Eveleigh, Nazanin Nourbehesht, Madeleine Arseneault, Antoine Paccard, Lars Egevad, Juris Viksna, Edgars Celms, Sharon M. Jackson, Behnoush Abedi-Ardekani, Anne Y. Warren, Peter J. Selby, Sebastian Trainor, Michael Kimuli, Jon Cartledge, Naeem Soomro, Adebanji Adeyoju, Poulam M. Patel, Magdalena B. Wozniak, Ivana Holcatova, Antonin Brisuda, Vladimir Janout, Estelle Chanudet, David Zaridze, Anush Moukeria, Oxana Shangina, Lenka Foretova, Marie Navratilova, Dana Mates, Viorel Jinga, Ljiljana Bogdanovic, Bozidar Kovacevic, Anne Cambon-Thomsen, Guillaume Bourque, Alvis Brazma, Jorg Tost, Paul Brennan, Mark Lathrop, Yasser Riazalhosseini, Rosamonde E. Banks

Summary: Targeted gene sequencing can help in risk prediction and adjuvant treatment decisions for patients with resected localized ccRCC. Mutations in the VHL gene have a significant impact on patient outcomes, independent of other gene mutations. Genomic characterization can personalize treatment discussions and inform future adjuvant trial design.

CLINICAL CANCER RESEARCH (2023)

Review Oncology

Tackling Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer

Juan Bautista Blaquier, Sandra Ortiz-Cuaran, Biagio Ricciuti, Laura Mezquita, Andres Felipe Cardona, Gonzalo Recondo

Summary: The landscape of targeted therapies for EGFR-mutant NSCLC is expanding, but resistance to treatment is a challenge. Understanding and using DNA sequencing has led to the development of innovative strategies to overcome or prevent resistance in the clinical setting.

CLINICAL CANCER RESEARCH (2023)

Editorial Material Pathology

Tumour grading: communication is the key

Murali Varma, Brett Delahunt, Liang Cheng, Runjan Chetty, Eva Comperat, Vikram Deshpande, Lars Egevad, Theodorus H. van der Kwast, Antonio Lopez-Beltran, W. Glenn McCluggage

JOURNAL OF CLINICAL PATHOLOGY (2023)

Article Biochemistry & Molecular Biology

Novel compounds that synergize with aminoglycoside G418 or eRF3 degraders for translational readthrough of nonsense mutant TP53 and PTEN

Angelos Heldin, Matko Cancer, Mireia Palomar-Siles, Susanne Ohlin, Meiqiongzi Zhang, Alexander Sun-Zhang, Anna Mariani, Jianping Liu, Vladimir J. N. Bykov, Klas G. G. Wiman

Summary: The TP53 and PTEN tumour suppressor genes are frequently inactivated by nonsense mutations in human tumours. In this study, two novel compounds were identified that can induce translational readthrough and restore the expression of full-length p53 protein in cells with TP53 nonsense mutations. Compound C47 showed synergy with G418, a known readthrough inducer, while compound C61 synergized with eRF3 degraders CC-885 and CC-90009. Furthermore, compound C47 also demonstrated potent induction of full-length PTEN protein in cells with different PTEN nonsense mutations. These findings may have implications for the development of targeted cancer therapy by pharmacologically inducing translational readthrough.

RNA BIOLOGY (2023)

Letter Pathology

Not all tumour necrosis is granular necrosis

Hemamali Samaratunga, Lars Egevad, Brett Delahunt

PATHOLOGY (2023)

Review Microbiology

The Hepatitis B Virus Genotypes E to J: The Overlooked Genotypes

Rayana Maryse Toye, Carmen Luisa Loureiro, Rossana Celeste Jaspe, Fabien Zoulim, Flor Helene Pujol, Isabelle Chemin

Summary: HBV genotypes E to J are understudied and have specific distributions across different regions. Genotype F is the most divergent and has further subgenotypes. There is a lack of data from sub-Saharan Africa and Latin America due to under-representation in clinical and research cohorts.

MICROORGANISMS (2023)

Review Pathology

Macroscopic examination of pathology specimens: a critical reappraisal

Murali Varma, Laura C. Collins, Runjan Chetty, Dipti M. Karamchandani, Karen Talia, John Dormer, Monika Vyas, Brendan Conn, Yaileen D. Guzman-Arocho, Adam Jones, Miranda Pring, W. Glenn Mccluggage

Summary: This paper highlights the importance of macroscopic examination and tissue sampling in histopathology reporting and discusses potential solutions and challenges. It emphasizes the need for adequate guidance and supervision in macroscopic examination and highlights the importance of clinical context, specimen fixation, macroscopic descriptions, and tissue sampling.

JOURNAL OF CLINICAL PATHOLOGY (2023)

Article Cell Biology

RNA helicase DDX5 modulates sorafenib sensitivity in hepatocellular carcinoma via the Wnt/β-catenin-ferroptosis axis

Zhili Li, Claud Caron de Fromentel, Woojun Kim, Wen-Hung Wang, Jiazeng Sun, Bingyu Yan, Sagar Utturkar, Nadia Atallah Lanman, Bennett D. Elzey, Yoon Yeo, Hao Zhang, Majid Kazemian, Massimo Levrero, Ourania Andrisani

Summary: The expression of DDX5 is reduced in hepatocellular carcinoma (HCC) and is associated with higher tumor grade and poor patient survival after sorafenib treatment. The study shows that DDX5 downregulation by sorafenib mediates adaptive resistance by activating the Wnt/beta-catenin signaling pathway, leading to ferroptosis escape. Conversely, overexpression of DDX5 enhances the efficacy of sorafenib by suppressing Wnt/beta-catenin activation and induction of ferroptosis.

CELL DEATH & DISEASE (2023)

No Data Available